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Abstract 18 
Background: Chagas disease is a tropical disease caused by the hemoflagellate 19 
protozoan Trypanosoma cruzi. There is no vaccine for Chagas disease and available 20 
drugs (e.g. benznidazole) are effective only during the acute phase, displaying a variable 21 
curative activity in the established chronic form of the disease. New leads with high 22 
efficacy and better toxicity profiles are urgently required. Methodology: A library of 23 
novel quinine derivatives was synthesised using Heck chemistry and evaluated against 24 
the various developmental forms of T. cruzi. Conclusions: Several novel quinine 25 
analogues with trypanocidal activity have been identified with the para-nitro-substituted 26 
derivative displaying a submicromolar IC50 which is 83 times lower than quinine and 27 
three times lower than benznidazole. Transmission electron microscopy analysis 28 
demonstrated that these compounds induced a marked vacuolisation of the kinetoplast 29 
of intracellular amastigotes and cell-derived trypomastigotes.  30 
 31 
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 35 
1. Introduction 36 
Chagas disease is a tropical neglected disease caused by the hemoflagellate protozoan 37 
Trypanosoma cruzi [1]. An estimated 6 million to 7 million people are infected 38 
worldwide, mostly in Latin America. Chagas disease has spread to other continents over 39 
the last century driven by movement of people and international trade. 40 
There is currently no vaccine for Chagas disease and the available drugs (nifurtimox 41 
and benznidazole) were developed more than four decades ago [2]. Both are effective 42 
only if given soon after infection at the onset of the acute phase. The efficacy of both 43 
diminishes, however, the longer a person has been infected [3]. These compounds do 44 
not completely reduce the parasite load in the bloodstream and may display serious side 45 
effects [4]. The associated side effects, including anorexia, vomiting, peripheral 46 
polyneuropathy and allergic dermopathy, can in some cases lead to treatment 47 
discontinuation [5]. Therefore, there is an on-going global effort to find new natural and 48 
synthetic compounds with high efficacy and less adverse side effects. 49 
Quinine is the major alkaloid found in the bark of various species of Cinchona 50 
(Rubiaceae) trees [6]. It was the first effective treatment for malaria until the 1940s, 51 
when other drugs with fewer side effects (such as chloroquine and artemisinin) replaced 52 
it [7]. More recently, it has been demonstrated that quinine possesses potent 53 
schizonticidal action against intra-erythrocytic malaria parasites [8]. Merschjohann and 54 
co-workers investigated the effect of 34 alkaloids on the growth of Trypanosoma brucei 55 
and T. congolense in vitro. Quinine, berbamine, berberine, cinchonidine, cinchonine, 56 
emetine, ergotamine, quinidine and sanguinarine showed trypanocidal activities with 57 
ED50 values below 10 µM [9]. Ruiz-Mesia et al. tested several Cinchona alkaloids 58 
isolated from Remijia peruviana against T. cruzi and found that only quinine displayed 59 
moderate trypanocidal activity [10]. A similar observation was also made by Sepúlveda-60 
Boza and Cassels [11].  61 
Given the well-known activity of quinine derivatives against the apicomplexan 62 
Plasmodium, we wondered if similar analogues might be effective against the 63 
pathogenic protozoan T. cruzi. Three main types of modification have been traditionally 64 
made to the quinine scaffold, namely modification of the quinolone/quinuclidine ring, 65 
substitution of the hydroxyl group or manipulation of the stereochemical configuration 66 
[12, 13]. It has been demonstrated that both the hydroxyl group and quinolone ring are 67 
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essential for antimalarial activity [14]. More recently, the terminal alkene in quinine has 68 
been identified as a versatile synthetic handle, particularly in the development of novel 69 
asymmetric catalysts [15-19]. The manipulation of this fragment in medicinal chemistry 70 
is less common. Significantly, Dinio et al. found that the introduction of aryl 71 
substituents was associated with higher potency against both quinine-sensitive and 72 
quinine-resistant strains of Plasmodium [20]. Furthermore, Bhattacharjee et al. have 73 
proposed a binding model which suggests that the quinine vinyl group may be important 74 
for activity [21].  75 
In view of these results, we sought to employ a similar strategy against T. cruzi. 76 
Modification of the alkene by way of Heck chemistry should be relatively straight 77 
forward [22]. A library of quinine analogues generated in this fashion should provide 78 
insights into the importance of the alkene functionality and highlight possible structure 79 
activity relationships.  80 
 81 
2 Experimental Protocols 82 
 83 
2.1 Reagents and data collection 84 
MTT (Thiazolyl Blue Tetrazolium Bromide) was purchased from Invitrogen (Carlsbad, 85 
CA, USA). Benznidazole, DAPI (4′,6-Diamidine-2′-phenylindole dihydrochloride), 86 
DMSO (dimethyl sulfoxide) and DMEM (Dulbecco's Modified Eagle's Medium) were 87 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum was 88 
purchased from Thermo Fisher Scientific (Carlbad, CA, USA). All solvents were 89 
purified and dried using standard methods prior to use. Commercially available reagents 90 
were used without further purification. The reactions were monitored by thin layer 91 
chromatography (TLC), using MERCK pre-coated silica gel 60-F254 aluminium plates. 92 
Visualisation of spots on TLC plates was done by UV light. Column chromatography 93 
with 230-400 mesh silica gel was used as the purification method. A gradient 94 
combination of dichloromethane and methanol was used as eluent. 1H-NMR spectra 95 
were recorded on an Avance NMR instrument operated at 400 MHz. 13C-NMR spectra 96 
were recorded on an Avance NMR instrument operated at 100 MHz. All spectra were 97 
recorded at room temperature (approximately 20 °C) in deuterated chloroform (CDCl3). 98 
Chemical shifts values were reported in ppm with TMS as an internal reference and J 99 
values were given in Hertz. The following abbreviation were used for 1H-NMR spectra 100 
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to indicate the signal multiplicity: s (singlet), d (doublet), dd (double doublet), ddd 101 
(double double doublet), m (multiplet). HRMS were determined with Waters LCT 102 
Premier Time of Flight spectrometer in electrospray ionisation (ESI) mode using 50% 103 
water/acetonitrile containing 0.1% formic acid as eluent and samples were made up in 104 
acetonitrile. 105 
 106 
2.2 General synthetic procedure for compounds 2-5 and 8-11 107 
Quinine (1) (250 mg, 0.77 mmol), palladium(II) acetate (8.7 mg, 0.039 mmol), and 108 
triphenylphosphine or tri(o-tolyl)phosphine (0.077 mmol, 10 mol%) were added to a 109 
sealed, oven-dried tube under an inert atmosphere of nitrogen. The aryl halide (1.54 110 
mmol, 2.0 equiv.) in degassed, anhydrous toluene (1.5 mL) was added to the reaction 111 
tube via syringe, followed by triethylamine or tributylamine (1.54 mmol, 2.0 equiv.). 112 
The reaction mixture was stirred at 111 °C until the reaction had reached completion. 113 
The reaction mixture was allowed to cool to room temperature and the solvent was 114 
removed in vacuo to furnish a reddish coloured semi-solid material. The crude solid was 115 
dissolved in dichloromethane (10 mL), filtered through a cotton plug and the resulting 116 
filtrate was concentrated in vacuo at 50-55 °C for 3 hours to fully remove the excess 117 
base. The residue was purified using silica gel column chromatography using a gradient 118 
solvent system of dichloromethane and MeOH (98:2 to 85:15). The fractions containing 119 
the product were combined and the solvent was removed in vacuo to afford the product 120 
as an amorphous solid.  121 
2.3 11-(Phenyl)-quinine (2)[20] 122 
Off-white solid, yield 89%; 1H-NMR (400MHz, CDCl3): δ 8.65 (1H, d, J = 4.4 Hz), 123 
7.76 (1H, d, J = 9.2 Hz), 7.61 (1H, d, J = 4.4 Hz), 7.10 (5H, m), 6.99 (2H, m), 6.58 (1H, 124 
m), 6.32 (1H, d, J = 15.8 Hz), 5.79 (1H, dd, J1 = 7.6 Hz, J2 = 15.8 Hz), 4.46 (1H, OH), 125 
3.70 (3H, s), 3.55 (1H, m), 3.42 (1H, m), 3.17 (2H, m), 3.03 (1H, m), 2.86 (1H, m), 2.20 126 
(2H, m), 1.88 (2H, m), 1.38 (1H, m); 13C-NMR (100MHz, CDCl3) : δ 158.7, 147.0, 127 
143.8, 143.6, 135.7, 133.02, 131.4, 128.6, 126.2, 122.8, 119.1, 100.1, 66.1, 60.4, 58.7, 128 
55.7, 44.5, 36.8, 27.6, 24.2, 18.8; HRMS (ESI): m/z mass calc for C26H29N2O3 (M+H+) 129 
401.2229, Found 401.2233. 130 
 131 
2.4 11-(Bis-3,5-trifluoromethyl)phenyl-quinine (3) 132 
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Off-white solid, yield 86%; 1H-NMR (300MHz, CDCl3): δ 8.70 (1H, d, J = 4.5 Hz), 133 
8.01 (1H, d, J = 9.2 Hz), 7.66 (2H, s), 7.40 (1H, dd, J1 = 2.6 Hz, J2 = 9.3 Hz), 7.26-7.31 134 
(5H, m), 7.20 (1H, m), 6.40 (1H, d, J = 16.1 Hz), 6.10 (1H, dd, J1 = 7.9 Hz, J2 = 16.1 135 
Hz), 5.29 (1H, s), 4.0 (3H, s), 3.45 (1H, m), 3.33 (2H, m), 2.97 (2H, m), 2.54 (1H, m), 136 
1.77 (1H, m), 1.67 (2H, m), 1.62 (2H, m); 13C-NMR (100MHz, CDCl3): δ 157.8, 147.7, 137 
144.4, 139.4, 138.0, 132.1, 132.0, 131.8, 128.5, 128.4, 127.6, 126.7, 125.8, 120.4, 138 
118.4, 101.5, 72.2, 60.4, 57.3, 55.7, 43.1, 39.9, 28.2, 27.6, 22.3; HRMS (ESI): m/z mass 139 
calc for C26H27N2O2F6 (M+H+) 537.1977 Found 537.1970. 140 
 141 
2.5 11-(3,4,5-Trifluorophenyl)-quinine (4) 142 
Off-white solid, yield 71%; 1H-NMR (400MHz, CDCl3): δ 8.69 (1H, d, J = 4.5 Hz), 143 
7.71 (1H, d, J = 9.2 Hz), 7.68 (1H, d, J = 4.5 Hz), 7.01 (1H, dd, J1 = 2.4 Hz, J2 = 9.2 144 
Hz), 6.94 (1H, d, J = 2.3 Hz),  6.75 (2H, m), 6.50 (1H, d, J = 16.1 Hz), 6.23 (1H, d, J = 145 
15.8 Hz), 5.81 (1H, dd, J1 = 7.6 Hz, J2 = 15.8 Hz), 4.55 (1H, OH), 3.66 (3H, s), 3.56 146 
(1H, m), 3.41 (1H, m), 3.16 (1H, m), 3.03 (1H, m), 2.85 (1H, m), 2.30 (1H, m), 2.16 147 
(2H, m), 1.90 (1H, m), 1.37 (1H, m);13C-NMR (100MHz, CDCl3): δ 158.3, 152.5, 148 
150.1, 147.0, 143.7, 143.6, 139.4, 131.4, 130.7, 130.2, 125.3, 122.3, 118.9, 110.2, 149 
110.0, 99.9, 66.1, 60.3, 57.6, 55.4, 44.3, 36.9, 27.5, 24.3, 21.1, 18.5; HRMS (ESI): m/z 150 
mass calc for C26H26N2O2F3 (M+H+) 455.1946 Found 455.1951. 151 
 152 
2.6 11-(2,4,6-Trifluorophenyl)-quinine (5) 153 
Off-white solid, yield 69%; 1H-NMR (300MHz, CDCl3): δ 8.69 (1H, d, J = 4.5 Hz), 8.0 154 
(1H, d, J = 9.2 Hz), 7.51 (1H, d, J = 4.5 Hz), 7.35 (1H, dd, J1 = 2.6 Hz, J2 = 9.3 Hz), 155 
7.27 (1H, d, J = 2.7 Hz), 6.84 (2H, m), 6.20 (1H, d, J = 15.8 Hz), 6.08 (1H, dd, J1 = 7.9 156 
Hz, J2 = 15.8 Hz), 5.55 (1H, d, J = 4.2 Hz), 3.92 (3H, s), 3.45 (1H, m), 3.18 (2H, m), 157 
2.69 (2H, m), 2.43 (1H, m), 1.87 (2H, m), 1.63 (1H, m), 1.53 (2H, m); 13C-NMR 158 
(100MHz, CDCl3): δ 164.2, 162.2, 157.8, 147.7, 147.4, 144.4, 136.2, 131.7, 127.5, 159 
126.7, 121.5, 118.3, 109.8, 109.6, 101.4, 72.2, 60.3, 57.4, 55.7, 43.1, 39.6, 28.2, 27.6, 160 
22.1; HRMS (ESI): m/z mass calc for C26H26N2O2F3 (M+H+) 455.1946 Found 161 
455.1942. 162 
 163 
2.7 11-(4-Nitrophenyl)-quinine (8) 164 
White solid, yield 82%; 1H-NMR (400MHz, CDCl3): δ 8.69 (1H, d, J = 4.5 Hz), 8.05 165 
(2H, m), 7.71 (1H, d, J = 9.2 Hz), 7.66 (1H, d, J = 4.5 Hz), 7.29 (2H, m),  6.99 (1H, dd, 166 
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J1 = 2.6 Hz, J2 = 9.2 Hz), 6.93 (1H, d, J = 2.3 Hz), 6.43 (1H, d, J = 16.1 Hz), 6.10 (1H, 167 
dd, J1 = 7.9 Hz, J2 = 16.1 Hz), 4.50 (1H, m), 3.66 (3H, s), 3.54 (1H, m), 3.33 (2H, m), 168 
3.13 (2H, m), 3.0 (1H, m), 2.88 (1H, m), 2.29 (1H, m), 1.88 (2H, m), 1.40 (2H, m); 13C-169 
NMR (100MHz, CDCl3): δ 158.1, 147.1, 147.0, 144.1, 143.6, 142.2, 133.6, 131.4, 170 
130.8, 126.8, 125.3, 124.0, 122.0, 118.8, 99.9, 66.4, 60.4, 56.9, 55.4, 44.1, 37.6, 27.5, 171 
24.6, 18.7; HRMS (ESI): m/z  mass calc for C26H27N3O4 (M+H+) 446.2080 Found 172 
446.2080. 173 
 174 
2.8 11-(4-Methoxyphenyl)-quinine (9)[20] 175 
Off-white solid, yield 68%; 1H-NMR (400MHz, CDCl3): δ 8.68 (1H, d, J = 4.5 Hz), 176 
7.71 (1H, d, J = 9.3 Hz), 7.69 (1H, d, J = 4.6 Hz), 7.16 (3H, m), 7.07 (1H, d, J = 8.6 177 
Hz), 6.99 (1H, dd, J1 = 2.3 Hz, J2 = 9.2 Hz), 6.92 (1H, d, J = 2.3 Hz), 6.71 (1H, d, J = 178 
8.7 Hz), 6.49 (1H, d, J = 15.8 Hz), 6.33 (1H, dd, J1 = 7.6 Hz, J2 = 15.8 Hz), 5.69 (1H, 179 
m), 4.55 (1H, m), 3.73 (3H, s), 3.65 (3H, s), 3.63 (1H, m), 3.55 (1H, m), 3.41 (1H, m), 180 
3.16 (2H, m), 3.0 (1H, m), 2.85 (1H, m), 2.29 (1H, m), 2.14 (2H, m), 1.90 (2H, m), 1.40 181 
(2H, m);  13C-NMR (100MHz, CDCl3): δ 158.3, 147.0, 143.9, 143.7, 132.8, 132.2, 182 
131.3, 128.6, 127.4, 126.2, 122.3, 119.0, 114.0, 99.8, 66.1, 60.4, 57.6, 55.8, 55.3, 44.3, 183 
37.0, 27.6, 24.4, 18.5; HRMS (ESI): m/z  mass calc for C26H30N2O3 (M+H+) 431.2335 184 
Found 431.2326. 185 
 186 
2.9 11-(4-Cyanophenyl)-quinine (10) 187 
Off-white solid, yield 63%; 1H-NMR (400MHz, CDCl3): δ 8.63 (1H, d, J = 4.48 Hz), 188 
7.70 (1H, d, J = 9.27 Hz), 7.59 (1H, d, J = 4.52), 7.42 (2H, m), 7.18 (2H, m),  6.98 (2H, 189 
m), 6.47 (1H, d, J = 15.8 Hz), 6.33 (1H, dd, J1 = 7.65 Hz, J2 = 15.78 Hz), 5.93 (1H, m), 190 
4.51 (1H, m), 3.63 (3H, s), 3.51 (1H, m), 3.47 (1H, m), 3.13 (2H, m), 3.0 (1H, m), 2.85 191 
(1H, m), 2.29 (1H, m), 2.13 (2H, m), 1.85 (2H, m), 1.37 (2H, m);  13C-NMR (100MHz, 192 
CDCl3): δ 158.3, 147.0, 143.9, 143.8, 143.6, 140.04, 132.4, 132.1, 131.5, 131.4, 126.8, 193 
122.2, 118.9, 111.4, 99.94, 66.1, 60.4, 57.6, 55.4, 44.1, 37.1, 27.5, 24.4, 18.6; HRMS 194 
(ESI): m/z mass calc for C27H27N3O2 (M+H+) 426.2182 Found 426.2178. 195 
 196 
2.10 11-(4-Methylphenyl)-quinine (11)[20] 197 
White solid, yield 87%; 1H-NMR (400MHz, CDCl3): δ 8.71 (1H, d, J = 4.51 Hz), 7.80 198 
(1H, d, J = 9.12 Hz), 7.70 (1H, d, J = 4.48 Hz), 7.45 (1H, d, J = 8.31 Hz), 7.25 (2H, m), 199 
7.10 (2H, m),  6.52 (1H, s), 6.42 (1H, d, J = 15.8 Hz), 5.97 (1H, dd, J1 = 7.70 Hz, J2 = 200 
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15.8 Hz), 4.55 (1H, m), 3.77 (3H, s), 3.59 (1H, m), 3.47 (1H, m), 3.18 (1H, m), 3.1 (1H, 201 
m), 2.94 (3H, m), 2.26 (3H, s), 1.90 (2H, m), 1.37 (2H, m);  13C-NMR (100MHz, 202 
CDCl3): δ 158.5, 147.2, 144.0, 143.7, 139.1, 131.7, 131.6, 130.9, 126.4, 125.6, 122.3, 203 
119.0, 100.1, 66.1, 60.4, 57.6, 55.8, 55.6, 47.6, 44.3, 37.1, 29.7, 27.7, 27.5, 24.4, 20.1, 204 
18.6; HRMS (ESI): m/z mass calc for C27H31N2O2 (M+H+) 415.2386 Found 415.2386. 205 
 206 
2.11 Synthetic procedure for (9S,8S)-9-amino-(9-deoxymethyl)-epiquinine (6)[19] 207 
Quinine (1) (2g, 6.16 mmol) and triphenylphosphine (2 g, 7.62 mmol) were charged to a 208 
three neck 100 mL RBF followed by 50 mL of dry tetrahydrofuran under a nitrogen 209 
atmosphere. The reaction was cooled to -5 °C and stirred until the solution turned clear. 210 
Diisopropyl azadicarboxylate (DIAD) (1.5 g, 7.42 mmol) was added dropwise via 211 
syringe at -5 °C. The reaction was stirred for 30 minutes before diphenylphosphoryl 212 
azide (DPPA) (2.1 g, 7.63 mmol) was added dropwise via syringe at -5 °C. The reaction 213 
mixture was heated to room temperature and stirred for a further 18 hours. The reaction 214 
mixture was subsequently stirred at 60 °C for 2 hours. Triphenylphosphine (2.1 g, 8.0 215 
mmol) was added and stirring continued for 4 hours. The reaction mixture was cooled to 216 
room temperature and deionised water (2.0 mL) was added before stirring for 18 hours. 217 
The solvent was removed in vacuo and the remaining aqueous layer was extracted with 218 
CH2Cl2:2M HCl (1:1, 80 mL). The dichlormethane layer was discarded and the aqueous 219 
layer was concentrated in vacuo. The crude product was purified via recrystallisation 220 
from hot methanol (4.0 mL) to afford (9S,8S)-9-amino-(9-deoxymethyl)-epiquinine 221 
hydrochloride as an off-white solid. The salt was basified with saturated sodium 222 
bicarbonate solution (20 mL) and extracted with CH2Cl2 (3 x 20 mL). Removal of the 223 
solvent in vacuo furnished (9S,8S)-9-amino-(9-deoxymethyl)-epiquinine (free base) as a 224 
yellow oil in 75% yield. 225 
1H-NMR (300 MHz, CDCl3): δ 8.75 (1H, d, J = 4.55 Hz), 8.04 (1H, d, J = 9.22 Hz), 226 
7.65 (1H, br, s), 7.45 (1H, d, J = 4.48 Hz), 7.39 (1H, dd, J1 = 2.75 Hz, J2 = 9.24 Hz), 227 
5.81 (1H, ddd, J1 = 7.35 Hz, J2 = 10.25 Hz, J3 = 17.52 Hz), 4.99 (2H, m), 4.60 (1H, d, J 228 
= 10.25 Hz), 3.97 (3H, s), 3.28 (1H, dd, J1 = 10.25 Hz, J2 = 13.85 Hz), 3.10 (1H, m), 229 
2.81 (2H, m), 2.28 (1H, m), 1.63 (1H, m), 1.56 (2H, m), 1.44 (1H, m);  13C-NMR 230 
(100MHz, CDCl3): δ 157.7, 147.9, 144.8, 141.8, 131.8, 128.8, 121.2, 119.9, 114.3, 231 
102.1, 61.9, 56.4, 55.6, 52.5, 41.0, 39.9, 28.2, 27.6, 26.1; HRMS (ESI): m/z  mass calc 232 
for C20H25N3O (M+H+) 324.2076 Found 324.2075. 233 
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 234 
2.12 Synthetic procedure for 11-phenyl-(9S,8S)-9-amino-(9-deoxymethyl)-epiquinine 235 
(7)[19] 236 
(9S,8S)-9-Amino-(9-deoxymethyl)-epiquinine (6) (100 mg, 0.31 mmol), palladium(II) 237 
acetate (3.48 mg, 0.0155 mmol), and triphenylphosphine (0.077 mmol, 0.031 mmol) 238 
were added to a sealed, oven-dried tube under an inert atmosphere of nitrogen. 239 
Iodobenzene (0.62 mmol, 2.0 equiv.) in degassed, anhydrous toluene (1.5 mL) was 240 
added to the reaction tube via syringe followed by triethylamine (0.62 mmol, 2.0 equiv). 241 
The reaction mixture was stirred at 111 °C until the reaction had reached completion 242 
after 18 h. The reaction mixture was allowed to cool to room temperature and the 243 
solvent was removed in vacuo to furnish a reddish coloured semi-solid material. The 244 
crude solid was dissolved in dichloromethane (10 mL) and filtered through a cotton 245 
plug. The resulting filtrate was concentrated in vacuo before extraction with CH2Cl2:2M 246 
HCl (1:1, 20 mL). The dichloromethane layer was discarded and the aqueous layer was 247 
concentrated in vacuo. The crude product was purified via recrystallisation from hot 248 
methanol (3.0 mL) to afford 11-phenyl-(9S,8S)-9-amino-(9-deoxymethyl)-epiquinine 249 
hydrochloride as a yellow solid. The salt was basified with saturated sodium 250 
bircarbonate solution (10 mL) and extracted with CH2Cl2 (2 x 10 mL). Removal of the 251 
solvent in vacuo furnished 11-phenyl-(9S,8S)-9-amino-(9-deoxymethyl)-epiquinine as a 252 
yellow solid in 84% yield. 253 
1H-NMR (300MHz, CDCl3): δ 8.77 (1H, d, J = 4.52 Hz), 8.04 (1H, d, J = 9.22 Hz), 7.51 254 
(1H, d, J = 4.32 Hz), 7.40 (1H, dd, J1 = 2.65 Hz, J2 = 9.34 Hz), 7.26-7.31 (5H, m), 7.20 255 
(1H, m), 6.40 (1H, d, J = 16.1 Hz), 6.18 (1H, dd, J1 = 7.94 Hz, J2 = 16.1 Hz), 4.68 (1H, 256 
s), 4.0 (3H, s), 3.45 (1H, m), 3.33 (2H, m), 2.97 (2H, m), 2.54 (1H, m), 1.77 (1H, m), 257 
1.67 (2H, m), 1.62 (2H, m); 13C-NMR (100MHz, CDCl3): δ 157.8, 147.9, 144.8, 137.2, 258 
132.6, 132.0, 130.5, 128.6, 127.3, 126.1, 121.4, 119.0, 101.3, 71.7, 61.3, 56.7, 55.8, 259 
52.2, 41.2, 39.0, 27.9, 27.7, 25.9; HRMS (ESI): m/z mass calc for C26H29N2O3 (M+H+) 260 
400.2389 Found 400.2389. 261 
 262 
2.13 Vero Cells 263 
Vero cells (ATCC CCL-81) were kept in 75 cm2 tissue culture flasks at 37 °C in a 264 
humidified 5% CO2 atmosphere with DMEM supplemented with 5% fetal bovine 265 
serum. For the weekly seeding, cell monolayers were washed twice with PBS (pH 7.2), 266 
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trypsinised and the detached cells were collected by centrifugation for 5 min at 800g. 267 
The cells were inoculated at 9x105 cells/flask in fresh medium and kept as described 268 
above. 269 
 270 
2.14 Parasites 271 
Epimastigote forms of Trypanosoma cruzi, clone Dm28c, were kept at 28 °C in LIT 272 
(Liver Infusion-Tryptose) medium supplemented with 10% inactivated fetal bovine 273 
serum, with passages at every three days. Parasites from 72-hour cultures were used for 274 
the experiments. 275 
Cell-derived trypomastigotes were obtained from the supernatant of previously infected 276 
Vero cell cultures and used for re-infections. Briefly, Vero cells (1.3x106 cells) and cell-277 
derived trypomastigotes (ratio 1:10) were seeded into 75 cm2 tissue culture flasks in 278 
DMEM medium. After 4 h of incubation, the cultures were washed with DMEM to 279 
remove non-internalized parasites and then kept in DMEM at 37 °C in a humidified 5% 280 
CO2 atmosphere. Cell-derived trypomastigotes were collected in the supernatant 96 h 281 
post-infection. 282 
 283 
2.15 Drug assays on epimastigotes 284 
Three-day-old culture epimastigotes were collected, adjusted to a concentration of 285 
5x106 cells/well in 100 µL LIT medium and seeded into 96 well plates. Different 286 
concentrations of the compounds were then added (final concentrations in 200 µL: 287 
3.125, 6.25, 12.5, 25, 50 and 100 µM) and the plates were incubated for 24 h at 28 ºC. 288 
Benznidazole (7.81, 15.625, 31.25, 62.5 and 125 µM) was used as a positive control. 289 
Cell viability was assessed by the MTT methodology [23]. Briefly, after incubation with 290 
the drugs, 50 µL MTT (previously prepared at 10 mg/mL in PBS) was added to each 291 
well, with final concentration of 2 mg/mL MTT per well. The plates were wrapped in 292 
aluminium foil, incubated for 4 h at 28 °C, centrifuged for 15 min at 500g and the 293 
supernatant was removed. For cell lysis, 50 µL of a SDS/HCl solution (10% SDS, 0.01 294 
M HCl) was added to each well. After solubilisation, absorbance of the samples was 295 
read at 570 nm in an ELISA plate reader (Biotek Model EL800, Winooski, VT, USA). 296 
Dose-response curves were obtained with GraphPad Prism software (La Jolla, CA, 297 
USA) and the IC50/24 h value (concentration that inhibits culture growth in 50%) was 298 
then calculated. Absorbance of untreated cells (negative control) was used as 100% cell 299 
viability. The percentage of no-viable cells in each treatment was estimated by 300 
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comparison with the negative control. Experiments were made in biological duplicate, 301 
each one in technical triplicate.  302 
 303 
2.16 Drug assays on intracellular amastigotes and cytotoxicity 304 
Vero cells (5x103 cells/well) and cell-derived trypomastigotes (ratio 1:20) were seeded 305 
into 96-well plates in DMEM medium. After 4 h of incubation, the cultures were 306 
washed with DMEM to remove non-internalized parasites and then kept in 300 µL 307 
DMEM at 37 °C in a humidified 5% CO2 atmosphere. After 24 h of incubation, the 308 
infected Vero cell cultures with intracellular amastigotes were incubated with DMEM 309 
containing different drug concentrations (final concentration ranging from 0.078 to 310 
2000 µM) in a total volume of 200 µL/well. After incubation for additional 24 h the 311 
plates were washed with PBS, fixed for 5 minutes with cold methanol and cell nuclei 312 
were stained with DAPI (5 µg/mL). Images were obtained with an Operetta imaging 313 
system (Perkin Elmer, Waltham, MA, USA) on the DAPI channel, at 20x 314 
magnification. About 30-40 fields per well were captured, each field with five stacked 315 
images. 316 
It has been shown that Operetta is a reliable methodology for amastigote counting [24]. 317 
By using the Operetta Imaging system Harmony Software (Perkin Elmer, USA) the 318 
following parameters were defined: (a) percentage of infected Vero cells, (b) number of 319 
amastigotes per host cell, and (c) the Infectivity Index (II = a x b). The IC50/24 h value 320 
was then estimated from II, by comparing with the control (100% viability). Dose-321 
response curves were obtained with GraphPad Prism software. For cytotoxicity with the 322 
synthetic compounds, the parameter used was the total number of Vero cell nuclei. All 323 
experiments were performed in a single biological experiment, in technical 324 
sextuplicates. The Selectivity Index was obtained according to the formula: 325 
SI=CC50/IC50.  326 
 327 
2.17 Drug assays on cell-derived trypomastigotes and cytotoxicity 328 
Cell-derived trypomastigotes were collected, adjusted to a concentration of 1x107 329 
cells/well in 100 µL DMEM medium and seeded into 96-well plates. Different 330 
concentrations of 9 were then added (final concentrations in 200 µL: 1.562, 3.125, 6.25, 331 
12.5, 25, 50 and 100 µM) and the plates were incubated for 2 h at 37 ºC (longer 332 
incubation times resulted in transformation into the amastigote form). Benznidazole (up 333 
to 1000 µM) was used as control. Cell viability was assessed by the MTT methodology, 334 
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by incubating with 2 mg/mL MTT for 2 h at 37 ºC. For cell lysis, 50 µL DMSO plus 50 335 
µL of a SDS/HCl solution  were added to each well. After solubilisation, absorbance of 336 
the samples was read at 570 nm in an ELISA plate reader and the IC50/2 h value was 337 
then estimated. 338 
For cytotoxicity, Vero cells (1.25x105 cells/ml) were seeded in 96-well plates, 100 µl 339 
per well, and cultivated for 24 h. Thereafter, different concentrations of 9 were added 340 
(final concentrations in 200 µL: 12.5, 25, 50 and 100 µM) and the plates were incubated 341 
for 2 h at 37 ºC. Cell viability was assessed by the MTT methodology. Briefly, after 342 
incubation with the drugs, 50 µL MTT (previously prepared at 10 mg/mL in PBS) was 343 
added to each well, with final concentration of 2 mg/mL MTT per well. The plates were 344 
wrapped in aluminium foil, incubated for 2 h at 37 °C. For cell lysis, 50 µL of DMSO 345 
was added to each well. After solubilisation, absorbance of the samples was read at 570 346 
nm in an ELISA plate reader. Dose-response curves were obtained with GraphPad 347 
Prism software (La Jolla, CA, USA) and the CC50/2 h value was calculated. Absorbance 348 
of untreated cells (control) was used as 100% cell viability. Experiments were made in 349 
biological duplicate.  350 
 351 
2.18 Infectivity assay 352 
Vero cells (6x106 cells/well) and 9-treated (IC50/2 h value) trypomastigotes (ratio 1:10) 353 
were seeded into 6-well plates in DMEM medium. After 2 h of incubation, the cultures 354 
were washed with DMEM to remove non-adherent parasites and then incubated for 355 
further 48 h. After this time the cell cultures were fixed for 5 minutes with cold 356 
methanol and the cell nuclei were stained with 5 µg/mL DAPI. The percentage of 357 
infected Vero cells and the total number of intracellular amastigotes was estimated by 358 
counting 2,000 host cells in 05 randomly selected microscopic fields photographed in a 359 
Leica DMI6000B fluorescence microscope (20x objective) associated to a Leica 360 
AF6000 deconvolution software (Leica Microsystems, Buffalo Grove, IL, USA). The 361 
Infectivity Index (II) was calculated as described previously. 362 
 363 
2.19 Scanning Electron Microscopy (SEM) 364 
Cell-derived trypomastigotes (4.5x107/well) were incubated for 2 h with 12.5 µM 9, 365 
washed with PBS and fixed for 2 h with 2.5% glutaraldehyde in 0.1 M cacodylate 366 
buffer, pH 7.2. The cells were then adhered for 10 minutes to glass coverslips 367 
previously coated with 0.1% poly-L-lysine. The cells were washed in 0.1 M cacodylate 368 
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buffer and post-fixed for 5 minutes with 1% osmium tetroxide in this same buffer. After 369 
washing in buffer the samples were dehydrated in graded acetone series and dried in a 370 
Leica CPD300 critical point drier (Leica Mikrosysteme GmbH, Vienna, Austria). The 371 
coverslips were adhered to SEM stubs and coated with 20-nm thick gold layer in a 372 
Leica EM ACE200 sputtering device. The cells were then observed in a Jeol 373 
JSM6010Plus-LA scanning electron microscope. Untreated trypomastigotes were used 374 
as control. 375 
Additionally, Vero cells (1.25x105/well) and 9-treated trypomastigotes (ratio 1:10) were 376 
seeded into 24-well plates in DMEM medium, each well containing a glass coverslip. 377 
The cell cultures were incubated for 2 h, washed with PBS to remove non-adherent 378 
parasites and the coverslips were then fixed with glutaraldehyde and processed as 379 
above.  380 
 381 
2.20 Transmission Electron Microscopy 382 
Infected Vero cells with intracellular amastigotes (24-hour-old cultures) were incubated 383 
for 24 h with 1, 8, 9 and 11 and then processed for conventional transmission electron 384 
microscopy. Briefly, the cell cultures were fixed for 2 h with 2.5% glutaraldehyde in 0.1 385 
M cacodylate buffer pH 7.2, washed in buffer and then post-fixed for 1 h with 1% 386 
osmium tetroxide in cacodylate buffer. The samples were dehydrated in graded acetone 387 
series and embedded in Embed812 resin (EMS, Hatfield, PA, USA). Ultrathin sections 388 
were collected on cupper grids, stained with uranyl acetate and lead citrate and observed 389 
under a Jeol 1400Plus transmission electron microscope at 80 kV. 390 
Cell-derived trypomastigotes (4.5x107/well) were incubated for 2 h with the IC50 value 391 
of 9 (12.5 µM), washed with PBS, fixed for 2 h with 2.5% glutaraldehyde in cacodylate 392 
buffer and processed as above. Furthermore, Vero cells (6x106 cells/well) and 9-treated 393 
trypomastigotes (ratio 1:10) were seeded into 6-well plates in DMEM medium. The cell 394 
cultures were incubated for 2 h, 24 h or 48 h, washed with PBS, and then fixed with 395 
glutaraldehyde and processed as above.  396 
 397 
 398 
3. Results and discussion 399 
3.1 Chemistry 400 
The synthetic route to the compound library is outlined in Figure 1. Based on our 401 
previous efforts to develop novel quinine-derived organocatalysts [19], the target 402 
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compounds 2 to 11 were synthesized via a palladium-catalysed Heck coupling of 403 
commercially available quinine and the appropriate aryl halide under a nitrogen 404 
atmosphere (Table 1). This Heck chemistry displayed high selectively, with the trans-405 
isomer being formed exclusively in each case. Conversion to the Heck product was 406 
found to be dependent on the choice of ligand and base, as well as the nature of the aryl 407 
halide. Palladium acetate in combination with triphenylphosphine proved generally 408 
efficacious, although recourse to tri(o-tolyl)phosphine was required in some cases 409 
(entries 3, 4). Likewise, while triethylamine was a suitable base for this reaction (entries 410 
1, 9), the higher reaction temperatures afforded by use of tri-n-butylamine generally 411 
afforded higher yields overall (entries 2-8). In terms of substrate scope, fluorinated aryl 412 
halides were found to be less reactive (entries 4, 5). The reactivity suffered further as 413 
the number of fluorines on the aryl ring was increased, with pentafluorophenyl iodide 414 
failing to react under optimised conditions. Finally, replacement of the hydroxyl with an 415 
amine group by way of a Mitsunobu-Staudinger reaction furnished 6 with complete 416 
inversion of stereochemistry. The resulting amine derivative was subjected to Heck 417 
coupling with phenyl iodide affording 7 in 84% yield as the trans-isomer.  418 
 419 
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Figure 1. Synthesis of quinine analogues; Reagents and conditions: (i) Pd(OAc)2 (5 mol%), 421 
triphenylphosphine or (tri-o-tolyl)phosphine (10 mol%), Ar-X (2 equiv.), triethylamine or tributylamine (2 422 
equiv.), toluene, reflux, N2, 24 h. (ii) DIAD (1.2 equiv.), diphenylphosphorylazide (1.3 equiv.), 423 
triphenylphosphine (2.6 equiv.), anhydrous tetrahydrofuran, -10 to 60 °C, 75%. (iii) Pd(OAc)2 (5 mol%), 424 
triphenylphosphine (10 mol%), Ph-I (2 equiv.), tributylamine (2 equiv.), toluene, reflux, N2, 24 h, 84%. 425 
 426 
Table 1. Optimised conditions for the synthesis of quinine analogues via Heck coupling 427 
Entry Compound Ar-X Ligand Base Time Yield 
1 2 
I
 
PPh3 Et3N 16 h 89% 
2 3 
Br
CF3
F3C
 
PPh3 n-Bu3N 24 h 86% 
3 4 
Br
F
F
F
 
P(o-tol)3 n-Bu3N 34 h 71% 
4 5 
Br
F
F
F  
P(o-tol)3 n-Bu3N 34 h 69% 
5 7 
I
 
PPh3 n-Bu3N 18 h 84% 
6 8 
Br
O2N  
PPh3 n-Bu3N 18 h 82% 
7 9 
Br
MeO  
PPh3 n-Bu3N 18 h 68% 
8 10 
Br
NC  
PPh3 n-Bu3N 18 h 63% 
9 11 
I
 
PPh3 Et3N 16 h 87% 
 428 
 429 
3.2 Biological evaluation 430 
Compounds 1 to 7 were initially screened against culture epimastigotes, in order to 431 
assess their possible trypanocidal activity. The existence of an intracellular 432 
epimastigote-like form as an intermediate stage within the mammalian host supports the 433 
preliminary screening of trypanocidal compounds on this non-infectious stage of the 434 
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parasite [25]. Naturally occurring quinine (1) showed very weak activity (IC50/24 h 435 
higher than 100 µM) (Table 2, entry 1). On foot of the promising results previously 436 
reported by Dinio et al., the introduction of an aryl-substituent onto the olefinic side 437 
chain was investigated [20]. This modification was accompanied by an increase in 438 
potency with phenyl-substituted 2 displaying an IC50/24 h of 31.37 µM (entry 2). This 439 
improved activity may be partially rationalised by the increase in lipophilicity 440 
associated with the presence of the non-polar phenyl ring (cLogP 4.12 vs. 2.51). 441 
Extending this logic further, fluorine is often used to modulate the physicochemical 442 
properties of drugs, such as lipophilicity or electron density [26]. Fluorinated analogues 443 
3-5 were found to be comparable to 2 (entries 3-5). Compound 3, which was the most 444 
lipophilic derivative (cLog P 5.87) with two trifluoromethyl substituents on the aromatic 445 
ring, was the best candidate within this group, with an IC50/24 h of 18.86 ± 3.9 µM 446 
(entry 3). We also wished to ascertain whether the secondary alcohol group was a 447 
prequisite for activity. Replacing the hydroxyl in quinine with an amine via Mitsunobu-448 
Staudinger chemistry afforded 6 which was, unsurprisingly, discovered to be inactive 449 
(entry 6). Indeed, culture epimastigotes remained alive in the presence of 100 µM of 6 450 
over six days, when the cultures were then discarded. However, when 6 was subjected 451 
to a palladium-mediated coupling with phenyl iodide to furnish 7, the phenyl-substituted 452 
product displayed activity similar to 2 in spite of the absence of the hydroxyl group 453 
(entries 7 vs 2).  454 
 455 
Table 2. Effect of quinine derivatives (1 to 11) and benznidazole (BZ, control drug) on 456 
different T. cruzi developmental forms (culture epimastigotes and intracellular 457 
amastigotes) and host Vero cells, with determination of Inhibitory Concentration 50% 458 
(IC50) and cytotoxicity 50% (CC50). SI = Selectivity Index (CC50/IC50). 459 
 460 
Entry Compound 
IC50 (µM) IC50 (µM) CC50 (µM) 
Vero cell 
SI 
Amastigote 
cLog P 
Epimastigote Amastigote 
1 1 >100 80.35 288.46 3.59 2.51 
2 2 31.37 ± 3.96 7.50 18.46 2.46 4.12 
3 3 18.86 ± 3.95 15.00 5.19 0.35 5.87 
4 4 40.29 ± 9.01 5.19 6.35 1.22 4.54 
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5 5 44.28 ± 4.55 17.31 22.50 1.30 4.54 
6 6 >100 818.18 1365.35 1.67 2.41 
7 7 35.14 ± 9.64 30.58 20.77 0.68 4.01 
8 8 55.32 ± 6.36 0.96 10.6 11.04 4.06 
9 9 11.30 ± 4.21 1.15 7.4 6.43 3.96 
10 10 63.98 ± 9.68 8.09 11.43 1.41 3.97 
11 11 40.89 ± 2.28 2.31 7.8 3.38 4.63 
12 BZ 59 3.07a 3920.00a 1276.87a  
IC50: inhibitory concentration for 50% of parasites after 24 h 461 
CC50: cytotoxic concentration for 50% of Vero cell cultures after 24 h 462 
SI: selectivity index 463 
BZ: benznidazole 464 
cLog P calculated using Chemaxon Marvinsketch software package. 465 
aSee ref 27[27] 466 
 467 
Since this initial screening had returned some promising results, these compounds were 468 
next tested against intracellular amastigotes. The majority were found to active with 469 
IC50 values ranging from 5 to 31 µM (Table 2, entries 2-5, 7 and Figure 2A-C), apart 470 
from quinine (80.35 µM, entry 1) and 6 (818.18 µM, entry 6) in line with earlier results. 471 
Notably, all compounds were more active against intracellular amastigotes than culture 472 
epimastigotes. The introduction of an aromatic ring was found to be strongly beneficial, 473 
with phenyl-substituted 2 being 10-fold more active than quinine (entry 2 vs 1). 474 
Similarly, phenyl-substituted 7 was 27 times more effective than amine 2 (entry 7 vs 6). 475 
The impact of the substitution pattern on the aromatic ring is apparent when comparing 476 
3,4,5-trifluorinated 4 to 2,4,6-trifluorinated 5. Despite both compounds being isomers of 477 
one another, 4 is over three times more potent than 5. All of the active compounds 478 
showed relatively high cytotoxicity against the host Vero cells (Figure 2D-F). Quinine 479 
and 6, the two inactive compounds, were significantly less cytotoxic. The best 480 
Selectivity Index (SI) value was obtained for quinine with an SI of 3.59.  481 
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482 
Figure 2. Dose response curves after incubation of T. cruzi intracellular 483 
amastigotes (A-C) and Vero cells (D-F) with different concentrations of compounds 484 
1 to 11. Compounds were grouped according to their lower (A, D), medial (B, E) or 485 
higher (C, F) activity.  486 
 487 
In a search for compounds with improved trypanocidal activity but with reduced 488 
cytotoxicity, a second set of quinine derivatives bearing para-substituted aromatic rings 489 
was synthesised. The different para-substituents included both electron-withdrawing 490 
(e.g. cyano- and nitro-) and electron-donating groups (e.g. methyl and methoxy). 491 
Gratifyingly, while these compounds displayed comparable activity against culture 492 
epimastigotes, they displayed noticeably higher activity against the intracellular 493 
amastigote forms (Table 2, entries 8-11 and Figure 2D-F). The IC50/24 h values ranged 494 
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from 1 to 8 µM, which was within the range of our control drug benznidazole (3.1 µM). 495 
The most potent compound, which incorporated a para-nitro, was 83 times more 496 
effective than quinine and three times more effective than benznidazole with a 497 
submicromolar IC50 of 0.96 µM (entry 8). The effectiveness of 8 was further confirmed 498 
by visualising the clearance of T. cruzi amastigotes in infected Vero cells incubated with 499 
8 at levels ranging from 0.078 µM to 10 µM (Figure 3). While the molecule with the 500 
most highly electron-withdrawing group was most active (entry 8), the compound with 501 
the most highly electron-donating group as almost as effective (entry 9), with no 502 
obvious relationship emerging between the nature of the substituents and biological 503 
activity. Although the effective concentration was reduced following the introduction of 504 
the para-substituents, the resulting compounds were still found to be toxic in 505 
mammalian cells. Nevertheless, the resulting selectivity indexes were better than that of 506 
quinine, with the most potent compound having the highest SI value (entry 8).  507 
 508 
 509 
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510 
Figure 3. Detection of T. cruzi amastigotes in infected Vero cells with the Operetta 511 
Imaging System using Harmony software. Images from a representative experiment 512 
with 8. Infected Vero cell cultures were incubated for 24 h with quinine derivatives and 513 
then fixed with methanol. Nuclei of host cells and intracellular amastigotes were stained 514 
with DAPI and then automatically counted. A. Untreated control; B. 0.078 µM 8; C. 515 
0.625 µM 8; D. 1.25 µM 8; E. 5 µM 8; F. 10 µM 8. Scale bar = 100 µm. 516 
 517 
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Since the best SI values were obtained with 8, 9 and 11, these were selected for further 518 
analysis by transmission electron microscopy to compare the ultrastructure of 519 
intracellular amastigotes in treated and untreated host cell cultures (Figure 4A). 520 
Incubation with quinine (reference compound) resulted in morphological alteration in 521 
the reservosomes (lysosome-related organelles), which appeared more electron-dense 522 
(Figure 4B). Interestingly, treatment with 8 resulted in no noticeable structural changes 523 
in the amastigotes (data not shown). By contrast, 9 induced a large vacuolisation of the 524 
kinetoplast, a specific region of the single mitochondrion where DNA (k-DNA) is 525 
accumulated (Figure 4C). This effect has previously been observed in T. cruzi treated 526 
with different drugs [28-30]. Compound 11 induced an enlargement of a vacuole close 527 
to the flagellar pocket membrane, which appears to be the contractile vacuole complex 528 
(Figure 4D). This osmo-regulation system is well characterized in T. cruzi epimastigotes 529 
[31, 32]. It is possible that these compounds are influencing the osmo-regulatory 530 
process of the parasite. 531 
 532 
533 
Figure 4. Ultrastructural analysis of intracellular T. cruzi amastigotes by 534 
transmission electron microscopy (TEM). Vero cells were incubated for 4 h with 535 
trypomastigotes (ratio 10:1) and then washed to remove non-adherent parasites. After 536 
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24 h, the infected cells were treated with the IC50 value of compounds and fixed for 537 
TEM. A: Untreated control. B: Quinine; reservosomes (R) lose their circular profile and 538 
appear with an electron-dense matrix. C: Compound 9; the asterisks indicate 539 
enlargement of the kinetoplast region. D: Compound 11; Note the enlargement of the 540 
contractile vacuole (CV), located close to the flagellar pocket. F: flagellum; G: Golgi 541 
complex; K: kinetoplast DNA; N: nucleus; R: reservosome. 542 
 543 
Due to the large morphological alteration induced in the amastigotes kinetoplast by 9, 544 
the effect of this compound was further analysed on cell-derived trypomastigotes. The 545 
IC50/2 h was estimated as 12.5 µM. Interestingly, in incubations for 2 h, the 546 
benznidazole solution had no effect up to 1000 µM, inhibiting at most 42% of 547 
trypomastigotes. However, 9 showed high cytotoxicity against Vero cells (CC50/2 548 
h=33.33 µM; SI=2.67) (Figure 5). The ultrastructure of 9-treated trypomastigotes was 549 
then analyzed by scanning (SEM) and transmission (TEM) electron microscopy (Figure 550 
6). By SEM, treated parasites appeared with a round body with pointed tips. By TEM, 551 
the parasites showed the same large vacuolization in the kinetoplast, as observed with 552 
the treated intracellular amastigotes.  553 
 554 
Figure 5. Determination of Vero cell cytotoxicity (CC50) (A) and effect on cell-555 
derived trypomastigotes (IC50) (B) for compound 9, after incubation for 2 h at 556 
37oC. 557 
 558 
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 559 
Figure 6. Scanning (A,B) and transmission (C,D) electron microscopy of cell-560 
derived trypomastigotes incubated for 2 h with 12.5 µM compound 9. Note the 561 
rounding of the middle portion of the cell body (B), when compared to the typical 562 
undulating morphology of untreated parasites (A). Observation by transmission electron 563 
microscopy (C, D) shows an enlargement of the kinetoplast region (asterisk in D). The 564 
kinetoplast DNA (K) also appears less compact than that of control parasites (C). N: 565 
nucleus; G: Golgi complex; FP: flagellar pocket; K: kinetoplast.  566 
 567 
Trypomastigotes treated with 9 were next used to infect Vero cells. It was noted that the 568 
round parasites were still able to adhere (Figure 7) and infect the host cells. The 569 
kinetoplast vacuolization of the resulting intracellular parasites was visible after 24 h 570 
(Figure 8A, B), but intracellular parasites with altered morphology were no longer 571 
visible after 48 h (Figure 8C, D). The percentage of infected cells (Table 3) was slightly 572 
reduced (about 20%), but there was a significant decrease in the number of intracellular 573 
amastigotes per cell after 48h post-infection (about 45%), when compared to untreated 574 
control cultures. Considering the infection index, the inhibition rate reached 55%. This 575 
result indicated that the treatment of trypomastigotes with 9 lead to decreased 576 
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infectivity, but the remaining parasites with normal morphology were able to maintain 577 
the infection.  578 
 579 
 580 
Figure 7. Scanning (A) and transmission (B) electron microscopy of Vero cells 2 h 581 
after infection. Trypomastigotes were treated with IC50/2 h 9 before to cell infection. 582 
Note that the round parasites are still able to adhere (A) and to enter (B) the host cells. 583 
 584 
Table 3. T. cruzi trypomastigotes were treated for 2 h with 12.5 µM (IC50/2 h) 9 and 585 
then used to infect Vero cell cultures. The percentage of host cell infection and the 586 
number of intracellular amastigotes was then estimated 48 h post infection. 587 
 % Infection amastigotes / cell Infectivity index 
Control 20.12 1.19 23.94 
9 16.31 0.66 10.76 
% Inhibition 18.94 44.54 55.04 
 588 
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589 
Figure 8. Transmission electron microscopy of intracellular T. cruzi amastigotes 24 590 
h (A, B) and 48h post-infection (C, D). A and C:  untreated controls. B and D: 591 
Infection with 9-treated trypomastigotes. Intracellular parasites with an enlarged 592 
kinetoplast are still present 24 h post-infection (B), but parasites with normal 593 
morphology prevail after 48 h and maintain the infection (D). C: cytostome; F: 594 
flagellum; G: Golgi complex; K, kinetoplast; N: nucleus. 595 
 596 
4. Conclusions 597 
Our data indicates that modification of the vinyl group in quinine, in particular by the 598 
incorporation of an aromatic ring, is associated with increased trypanocidal activity 599 
against T. cruzi. Both the substitution pattern and choice of substituents on the ring were 600 
found to impact on potency. Para-substituted derivatives were discovered to be 601 
especially effective, with para-nitro-substituted 8 displaying a submicromolar IC50 602 
which is 83 times lower than quinine and three times lower than benznidazole. These 603 
compounds were less cytotoxic than the quinine lead, with the most efficacious 604 
compound 8 having an SI value of 11.04. We have further shown that these molecules 605 
can induce significant morphological changes including large kinetoplast vacuolisation 606 
in both intracellular amastigotes and cell-derived trypomastigotes. In summary, this 607 
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work demonstrates that modification of the quinine scaffold, in particular by 608 
incorporation of an aryl ring onto the vinyl group, affords compounds with high 609 
trypanocidal activity against T. cruzi. Such an approach offers significant potential for 610 
the development of new drugs for the treatment of Chagas disease. 611 
5. Future Perspective 612 
Many millions of people worldwide are infected with T. cruzi, the causative agent of 613 
Chagas disease. In spite of this, Chagas remains a neglected disease, with the main 614 
treatments having been developed many decades ago. Long term use of these therapies 615 
is associated with severe side-effects and instances of treatment failure are becoming 616 
increasingly common. Additionally, while Chagas disease was once largely confined to 617 
Latin America, it has become more widespread in recent years due to increased 618 
population movements. Indeed, some have suggested that an increase in global 619 
temperatures due to climate change may lead to even greater global prevalence. These 620 
factors underline the importance of developing new, safe and efficacious alternatives. 621 
Quinine has long been used as an anti-parasitic compound, but had fallen out of favour 622 
with the introduction of cheaper and more effective aminoquinolines such as 623 
chloroquine. However, increased parasite resistance has resulted in renewed interest in 624 
quinine, both as a standalone medication or in combination with other drugs with 625 
complemtary modes of action. This interest is also partly due to the versatile nature of 626 
the quinine molecule which offers multiple opportunities for further manipulation. 627 
Furthermore, advances in synthetic chemistry, such as palladium-catalysed carbon-628 
carbon bond formation, have facilitated the modification of the quinine scaffold in novel 629 
ways. This combination of “old molecules” with “new chemistry” opens up new 630 
avenues for the development of effective leads in treating neglected, parasitic diseases.  631 
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 645 
Executive Summary: 646 
-Novel, aryl-substituted analogues of quinine display significantly increased 647 
trypanocidal activity against T. cruzi. 648 
-Para-substituted aromatic analogues are especially potent, with the para-nitro-649 
derivative displaying a submicromolar IC50 which is three times lower than 650 
benznidazole. 651 
-Compounds with either electron-donating and electron-withdrawing substituents in the 652 
para-position are equally effective. 653 
-Analysis by transmission electron microscopy analysis confirmed that that these 654 
compounds induced a marked vacuolisation of the kinetoplast of T. cruzi intracellular 655 
amastigotes and cell-derived trypomastigotes. 656 
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